What Are Analysts Saying About Viatris Inc (VTRS) Stock?

Viatris Inc. (NASDAQ:VTRS) is one of the 13 extreme value stocks to buy now. Viatris Inc. (NASDAQ:VTRS) is covered by 12 analysts on Wall Street with a medium price target of $16, suggesting 12.36% upside from current levels. On February 27, Truist Financial analyst Les Sulewski raised the firmโ€™s price target on the stock from…


What Are Analysts Saying About Viatris Inc (VTRS) Stock?
What Are Analysts Saying About Viatris Inc (VTRS) Stock?

Viatris Inc. (NASDAQ:VTRS) is one of the 13 extreme value stocks to buy now. Viatris Inc. (NASDAQ:VTRS) is covered by 12 analysts on Wall Street with a medium price target of $16, suggesting 12.36% upside from current levels. On February 27, Truist Financial analyst Les Sulewski raised the firmโ€™s price target on the stock from $16 to $18 while reaffirming a Buy rating. The price target came just after the company announced its fourth-quarter financial results.

UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve
UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve

Viatris Inc. (NASDAQ:VTRS) posted its Q4 fiscal 2025 results on February 26, reporting revenue of $3.7 billion. This reflects 1% year-over-year growth when excluding the impact related to the Indore facility. The company generated $14.3 billion in revenue for the full year 2025. During the year, the company returned more than $1 billion to shareholders.

Free cash flow for the year reached $2.2 billion, excluding costs related to transactions. Looking ahead, management expects earnings and revenue to improve in the second half of 2026, supported by upcoming product launches and seasonality. Management expects to continue the current momentum in 2026, forecasting around 2% growth in both adjusted EBITDA and total revenue. Viatris Inc. (NASDAQ:VTRS) also anticipates generating between $450 million and $550 million in revenue from new product launches during the year.

Viatris Inc. (NASDAQ:VTRS) is a healthcare company operating across Japan, Europe, Hong Kong, Africa, North America, Australia, the Middle East, New Zealand, Taiwan, Latin America, China, and the rest of Asia. The company operates through the JANZ, Developed Markets, Emerging Markets, and Greater China segments.

While we acknowledge the potential of VTRSย  as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If youโ€™re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Yearsย 

Disclosure: None. Follow Insider Monkey on Google News.

Source link